| Non-Small Cell Lung Carcinoma

Rybrevant vs Tecentriq

Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.

Deep comparison between: Rybrevant vs Tecentriq with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecentriq has a higher rate of injection site reactions vs Rybrevant based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecentriq but not Rybrevant, including UnitedHealthcare

Category

Rybrevant

Tecentriq

At A Glance

RouteIntravenous

FrequencyWeekly x 4-5 weeks, then every 2-3 weeks

ClassBispecific EGFR/MET antibody

RouteIV infusion

FrequencyEvery 2-4 weeks

ClassPD-L1 antagonist

Indications

Non-Small Cell Lung Carcinoma

Non-Small Cell Lung Carcinoma
Small cell carcinoma of lung
Liver carcinoma
Melanoma
Alveolar Soft Part Sarcoma

Dosing

Non-Small Cell Lung Carcinoma (EGFR Exon 19 Del or L858R, first-line with lazertinib) 1,050 mg (<80 kg) or 1,400 mg (>=80 kg) IV weekly for 5 weeks (Week 1 split over Day 1 and Day 2), then every 2 weeks starting Week 7.

Non-Small Cell Lung Carcinoma (EGFR Exon 19 Del or L858R, post-TKI with chemotherapy) 1,400 mg (<80 kg) or 1,750 mg (>=80 kg) IV weekly for 4 weeks (Week 1 split over Day 1 and Day 2), then 1,750 mg (<80 kg) or 2,100 mg (>=80 kg) every 3 weeks starting Week 7, in combination with carboplatin AUC 5 every 3 weeks for up to 12 weeks and pemetrexed 500 mg/m2 every 3 weeks.

Non-Small Cell Lung Carcinoma (EGFR Exon 20 insertion, first-line with chemotherapy) 1,400 mg (<80 kg) or 1,750 mg (>=80 kg) IV weekly for 4 weeks (Week 1 split over Day 1 and Day 2), then 1,750 mg (<80 kg) or 2,100 mg (>=80 kg) every 3 weeks starting Week 7, in combination with carboplatin AUC 5 every 3 weeks for up to 12 weeks and pemetrexed 500 mg/m2 every 3 weeks.

Non-Small Cell Lung Carcinoma (EGFR Exon 20 insertion, post-platinum as single agent) 1,050 mg (<80 kg) or 1,400 mg (>=80 kg) IV weekly for 5 weeks (Week 1 split over Day 1 and Day 2), then every 2 weeks starting Week 7.

Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.

Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.

Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.

Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.

Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.

Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.

Contraindications

—

Drug Interactions

162View drug interactions

188View drug interactions

Adverse Reactions

Most common (>=20%) Rash (72-90%), nail toxicity (45-71%), infusion-related reaction (42-64%), fatigue (32-51%), musculoskeletal pain (30-47%), stomatitis (26-43%), edema (27-43%), nausea (21-45%), constipation (23-39%), decreased appetite (24-36%), diarrhea (15-31%), vomiting (12-25%), VTE (36% in combination with lazertinib), paresthesia (35% in combination with lazertinib), hemorrhage (25% in combination with lazertinib), dry skin (25% in combination with lazertinib), pruritus (24% in combination with lazertinib), COVID-19 (21-26%), dyspnea (37% as single agent), cough (17-25%), paronychia (50% as single agent).

Serious Infusion-related reactions including anaphylaxis, interstitial lung disease/pneumonitis, venous thromboembolic events (11% in combination with lazertinib), dermatologic reactions including toxic epidermal necrolysis, ocular toxicity.

Postmarketing Anaphylaxis/anaphylactic reactions.

Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).

Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.

Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.

Pharmacology

Amivantamab-vmjw is a bispecific antibody that binds EGFR and MET extracellular domains, disrupting ligand binding and receptor degradation, and targeting tumor cells for immune-mediated destruction via ADCC and trogocytosis.

Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Rybrevant